Pseudoviral immunity - a novel concept for lupus

Trends in Molecular Medicine

Volumn 15, Issue 12, 2009, Pages 553-561

  Anders, Hans Joachim ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON MONOCLONAL ANTIBODY; BETA INTERFERON; HISTONE; INTERFERON ANTIBODY; MONOCLONAL ANTIBODY; MYELOID DIFFERENTIATION FACTOR 88; NUCLEIC ACID; OLIGONUCLEOTIDE; RIBONUCLEOPROTEIN; RIBOSOME DNA OLIGONUCLEOTIDE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 7; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CHROMATIN; CYTOKINE RELEASE; DNA METHYLATION; DRUG TARGETING; GENETIC POLYMORPHISM; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSTIMULATION; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; PATHOGENICITY; PSEUDOVIRUS IMMUNITY; RISK FACTOR; RNA METHYLATION; SENSOR; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; ULTRASTRUCTURE; VIRUS IMMUNITY; VIRUS INFECTION; VIRUS PARTICLE;

ADAPTIVE IMMUNITY; ANTIGEN-PRESENTING CELLS; ANTIGENS, VIRAL; AUTOANTIGENS; AUTOIMMUNITY; B-LYMPHOCYTES; CHROMATIN; DNA, VIRAL; HUMANS; INFLAMMATION; INTERFERON TYPE I; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; OLIGONUCLEOTIDES; RIBONUCLEOPROTEINS; RISK FACTORS; RNA, VIRAL; T-LYMPHOCYTES; TOLL-LIKE RECEPTORS; VIRUSES;

EID: 70749096596     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2009.10.004     Document Type: Article

References (98)

1. Rahman A., and Isenberg D.A. Systemic lupus erythematosus. N. Engl. J. Med. 358 (2008) 929-939
2. Moser K.L., et al. Recent insights into the genetic basis of systemic lupus erythematosus. Genes Immun. 10 (2009) 373-379
3. Gaffney P.M., et al. A genome-wide search for susceptibility genes in human systemic lupus erythematosus sib-pair families. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 14875-14879
4. Nagata S. Autoimmune diseases caused by defects in clearing dead cells and nuclei expelled from erythroid precursors. Immunol. Rev. 220 (2007) 237-250
5. Marshak-Rothstein A., and Rifkin I.R. Immunologically active autoantigens: the role of toll-like receptors in the development of chronic inflammatory disease. Annu. Rev. Immunol. 25 (2007) 419-441
6. Kyogoku C., and Tsuchiya N. A compass that points to lupus: genetic studies on type I interferon pathway. Genes Immun. 8 (2007) 445-455
7. Jacob C.O., et al. Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus. Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 6256-6261
8. Takeuchi O., and Akira S. Innate immunity to virus infection. Immunol. Rev. 227 (2009) 75-86
9. Alexopoulou L., et al. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413 (2001) 732-738
10. Tamura T., et al. The IRF family transcription factors in immunity and oncogenesis. Annu. Rev. Immunol. 26 (2008) 535-584
11. Patole P.S., et al. Expression and regulation of Toll-like receptors in lupus-like immune complex glomerulonephritis of MRL-Fas(lpr) mice. Nephrol. Dial. Transplant. 21 (2006) 3062-3073
12. Wang T., et al. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat. Med. 10 (2004) 1366-1373
13. Le Goffic R., et al. Detrimental contribution of the Toll-like receptor (TLR)3 to influenza A virus-induced acute pneumonia. PLoS Pathog. 2 (2006) e53
14. Hoebe K., et al. Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature 424 (2003) 743-748
15. Heil F., et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303 (2004) 1526-1529
16. Baenziger S., et al. Triggering TLR7 in mice induces immune activation and lymphoid system disruption, resembling HIV-mediated pathology. Blood 113 (2009) 377-388
17. Lund J.M., et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 5598-5603
18. Zucchini N., et al. Cutting edge: overlapping functions of TLR7 and TLR9 for innate defense against a herpesvirus infection. J. Immunol. 180 (2008) 5799-5803
19. Town T., et al. Toll-like receptor 7 mitigates lethal West Nile encephalitis via interleukin 23-dependent immune cell infiltration and homing. Immunity 30 (2009) 242-253
20. Zhang S.Y., et al. Human Toll-like receptor-dependent induction of interferons in protective immunity to viruses. Immunol. Rev. 220 (2007) 225-236
21. Hochrein H., et al. Herpes simplex virus type-1 induces IFN-alpha production via Toll-like receptor 9-dependent and -independent pathways. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 11416-11421
22. Samuelsson C., et al. Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection. J. Clin. Invest. 118 (2008) 1776-1784
23. Tabeta K., et al. Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 3516-3521
24. von Bernuth H., et al. Pyogenic bacterial infections in humans with MyD88 deficiency. Science 321 (2008) 691-696
25. Takaoka A., et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 448 (2007) 501-505
26. Hornung V., et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 458 (2009) 514-518
27. Baccala R., et al. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat. Med. 13 (2007) 543-551
28. Chiu Y.H., et al. RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway. Cell 138 (2009) 576-591
29. Ablasser A., et al. RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate. Nat. Immunol. 10 (2009) 1065-1072
30. Stacey K.J., et al. The molecular basis for the lack of immunostimulatory activity of vertebrate DNA. J. Immunol. 170 (2003) 3614-3620
31. Kariko K., et al. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23 (2005) 165-175
32. Huck S., et al. Abnormal DNA methylation and deoxycytosine-deoxyguanine content in nucleosomes from lymphocytes undergoing apoptosis. FASEB J. 13 (1999) 1415-1422
33. Hof D., et al. Apoptotic modifications affect the autoreactivity of the U1 snRNP autoantigen. Autoimmun. Rev. 4 (2005) 380-388
34. Richardson B., et al. Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 33 (1990) 1665-1673
35. Cornacchia E., et al. Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J. Immunol. 140 (1988) 2197-2200
36. Strasser A., et al. The many roles of FAS receptor signaling in the immune system. Immunity 30 (2009) 180-192
37. Bickerstaff M.C., et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat. Med. 5 (1999) 694-697
38. Russell A.I., et al. Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum. Mol. Genet. 13 (2004) 137-147
39. Truedsson L., et al. Complement deficiencies and systemic lupus erythematosus. Autoimmunity 40 (2007) 560-566
40. Hanayama R., et al. Autoimmune disease and impaired uptake of apoptotic cells in MFG-E8-deficient mice. Science 304 (2004) 1147-1150
41. Napirei M., et al. Features of systemic lupus erythematosus in Dnase1-deficient mice. Nat. Genet. 25 (2000) 177-181
42. Yasutomo K., et al. Mutation of DNASE1 in people with systemic lupus erythematosus. Nat. Genet. 28 (2001) 313-314
43. Rice G., et al. Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant Aicardi-Goutieres syndrome. Am. J. Hum. Genet. 80 (2007) 811-815
44. Anders H.J., et al. Molecular mimicry in innate immunity? The viral RNA recognition receptor TLR7 accelerates murine lupus. Eur. J. Immunol. 38 (2008) 1795-1799
45. Savarese E., et al. U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7. Blood 107 (2006) 3229-3234
46. Barrat F.J., et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med. 202 (2005) 1131-1139
47. Christensen S.R., et al. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25 (2006) 417-428
48. Savarese E., et al. Requirement of Toll-like receptor 7 for pristane-induced production of autoantibodies and development of murine lupus nephritis. Arthritis Rheum. 58 (2008) 1107-1115
49. Pisitkun P., et al. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 312 (2006) 1669-1672
50. Berghofer B., et al. TLR7 ligands induce higher IFN-alpha production in females. J. Immunol. 177 (2006) 2088-2096
51. Leadbetter E.A., et al. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416 (2002) 603-607
52. Means T.K., et al. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J. Clin. Invest. 115 (2005) 407-417
53. Lenert P., et al. DNA-like class R inhibitory oligonucleotides (INH-ODNs) preferentially block autoantigen-induced B-cell and dendritic cell activation in vitro and autoantibody production in lupus-prone MRL-Faslpr/lpr mice in vivo. Arthritis Res. Ther. 11 (2009) R79
54. Patole P.S., et al. G-rich DNA suppresses systemic lupus. J. Am. Soc. Nephrol. 16 (2005) 3273-3280
55. Dong L., et al. Suppressive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong survival in lupus-prone NZB × NZW mice. Arthritis Rheum. 52 (2005) 651-658
56. Wang J., et al. The functional effects of physical interactions among Toll-like receptors 7, 8, and 9. J. Biol. Chem. 281 (2006) 37427-37434
57. Kariko K., et al. mRNA is an endogenous ligand for Toll-like receptor 3. J. Biol. Chem. 279 (2004) 12542-12550
58. Christensen S.R., et al. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J. Exp. Med. 202 (2005) 321-331
59. Lichtnekert J., et al. Trif is not required for immune complex glomerulonephritis: dying cells activate mesangial cells via Tlr2/Myd88 rather than Tlr3/Trif. Am. J. Physiol. Renal Physiol. 296 (2009) F867-F874
60. Theofilopoulos A.N., et al. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu. Rev. Immunol. 23 (2005) 307-336
61. Sadler A.J., and Williams B.R. Interferon-inducible antiviral effectors. Nat. Rev. Immunol. 8 (2008) 559-568
62. Han G.M., et al. Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. Genes Immun. 4 (2003) 177-186
63. Blanco P., et al. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 294 (2001) 1540-1543
64. Ronnblom L., et al. Type I interferon and lupus. Curr. Opin. Rheumatol. 21 (2009) 471-477
65. Nacionales D.C., et al. Deficiency of the type I interferon receptor protects mice from experimental lupus. Arthritis Rheum. 56 (2007) 3770-3783
66. Santiago-Raber M.L., et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J. Exp. Med. 197 (2003) 777-788
67. Braun D., et al. Type I interferon controls the onset and severity of autoimmune manifestations in lpr mice. J. Autoimmun. 20 (2003) 15-25
68. Hron J.D., and Peng S.L. Type I IFN protects against murine lupus. J. Immunol. 173 (2004) 2134-2142
69. Schwarting A., et al. Interferon-beta: a therapeutic for autoimmune lupus in MRL-Faslpr mice. J. Am. Soc. Nephrol. 16 (2005) 3264-3272
70. Lu Q., et al. Genomic view of IFN-alpha response in pre-autoimmune NZB/W and MRL/lpr mice. Genes Immun. 8 (2007) 590-603
71. Grimley P.M., et al. Tubuloreticular inclusions in peripheral blood mononuclear cells related to systemic therapy with alpha-interferon. Lab. Invest. 52 (1985) 638-649
72. Strauss J., et al. Renal disease in children with the acquired immunodeficiency syndrome. N. Engl. J. Med. 321 (1989) 625-630
73. Rich S.A. Human lupus inclusions and interferon. Science 213 (1981) 772-775
74. Yang A.H., et al. The clinicopathological implications of endothelial tubuloreticular inclusions found in glomeruli having histopathology of idiopathic membranous nephropathy. Nephrol. Dial. Transplant. 24 (2009) 3419-3425
75. Peterson K.S., et al. Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli. J. Clin. Invest. 113 (2004) 1722-1733
76. Rozzo S.J., et al. Evidence for an interferon-inducible gene, Ifi202, in the susceptibility to systemic lupus. Immunity 15 (2001) 435-443
77. Anders H.J. Innate pathogen recognition in the kidney: toll-like receptors, NOD-like receptors, and RIG-like helicases. Kidney Int. 72 (2007) 1051-1056
78. Flür K, Allam R, Zecher D, Kulkarni OP, Lichtnekert J, Schwarz M, Beutler B, Vielhauer V, Anders HJ. (2009) Viral RNA induces type I interferon-dependent cytokine release and cell death in mesangial cells via melanoma-differentiation-associated gene-5. Implications for viral infection-associated glomerulonephritis. Am. J. Pathol. [Epub ahead of print]
79. Allam R., et al. Viral RNA and DNA sense common antiviral responses including type I interferons in mesangial cells. J. Am. Soc. Nephrol. 20 (2009) 1986-1996
80. Hagele H., et al. Double-stranded RNA activates type I interferon secretion in glomerular endothelial cells via retinoic acid-inducible gene (RIG)-1. Nephrol. Dial. Transplant. 24 (2009) 3312-3318
81. Garlanda C., et al. TIR8/SIGIRR: an IL-1R/TLR family member with regulatory functions in inflammation and T cell polarization. Trends Immunol. 30 (2009) 439-446
82. Lech M., et al. Different roles of TiR8/Sigirr on toll-like receptor signaling in intrarenal antigen-presenting cells and tubular epithelial cells. Kidney Int. 72 (2007) 182-192
83. Huang X., et al. SIGIRR promotes resistance against Pseudomonas aeruginosa keratitis by down-regulating type-1 immunity and IL-1R1 and TLR4 signaling. J. Immunol. 177 (2006) 548-556
84. Garlanda C., et al. Damping excessive inflammation and tissue damage in Mycobacterium tuberculosis infection by Toll IL-1 receptor 8/single Ig IL-1-related receptor, a negative regulator of IL-1/TLR signaling. J. Immunol. 179 (2007) 3119-3125
85. Wald D., et al. SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling. Nat. Immunol. 4 (2003) 920-927
86. Lech M., et al. Tir8/Sigirr prevents murine lupus by suppressing the immunostimulatory effects of lupus autoantigens. J. Exp. Med. 205 (2008) 1879-1888
87. O'Neill L.A. When signaling pathways collide: positive and negative regulation of toll-like receptor signal transduction. Immunity 29 (2008) 12-20
88. Espinosa A., et al. Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23-Th17 pathway. J. Exp. Med. 206 (2009) 1661-1671
89. Kawagoe T., et al. TANK is a negative regulator of Toll-like receptor signaling and is critical for the prevention of autoimmune nephritis. Nat. Immunol. 10 (2009) 965-972
90. Gilliet M., et al. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat. Rev. Immunol. 8 (2008) 594-606
91. Kerkmann M., et al. Spontaneous formation of nucleic acid-based nanoparticles is responsible for high interferon-alpha induction by CpG-A in plasmacytoid dendritic cells. J. Biol. Chem. 280 (2005) 8086-8093
92. Boule M.W., et al. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J. Exp. Med. 199 (2004) 1631-1640
93. Van Ghelue M., et al. Autoimmunity to nucleosomes related to viral infection: a focus on hapten-carrier complex formation. J. Autoimmun. 20 (2003) 171-182
94. Vollmer J., et al. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J. Exp. Med. 202 (2005) 1575-1585
95. Pawar R.D., et al. Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. J. Am. Soc. Nephrol. 18 (2007) 1721-1731
96. Barrat F.J., et al. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur. J. Immunol. 37 (2007) 3582-3586
97. Yao Y., et al. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum. 60 (2009) 1785-1796
98. Yoshida H., et al. Lethal anemia caused by interferon-beta produced in mouse embryos carrying undigested DNA. Nat. Immunol. 6 (2005) 49-56